Evidence map›Paper›PMID 41062303›Full record

ArticleMagnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine2026

Diagnostic Potential of Macromolecular Proton Fraction Mapping Combined with Quantitative Susceptibility Mapping as a Subcortical Biomarker for Parkinson's Disease.

Yasuhiro Fujiwara, Nobutaka Sakae, Hiroyuki Kumazoe, Kouta Miyamoto, Yoshinori Hirakawa, Hirohito Kan, Kosuke Yamashita, Mika Kitajima

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yasuhiro FujiwaraDepartment of Medical Imaging Technology, Faculty of Life Sciences, Kumamoto University, Kumamoto Kumamoto, Japan.
Nobutaka SakaeDepartment of Neurology, National Hospital Organization Omuta National Hospital, Omuta Fukuoka, Japan.
Hiroyuki KumazoeDepartment of Radiology, National Hospital Organization Omuta National Hospital, Omuta Fukuoka, Japan.
Kouta MiyamotoDepartment of Radiology, National Hospital Organization Omuta National Hospital, Omuta Fukuoka, Japan.
Yoshinori HirakawaDepartment of Radiology, National Hospital Organization Omuta National Hospital, Omuta Fukuoka, Japan.
Hirohito KanDepartment of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya Aichi, Japan.
Kosuke YamashitaDepartment of Medical Imaging Technology, Faculty of Life Sciences, Kumamoto University, Kumamoto Kumamoto, Japan.
Mika KitajimaDepartment of Diagnostic Imaging Technology, Faculty of Life Sciences, Kumamoto University, Kumamoto Kumamoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to evaluate the diagnostic potential of macromolecular proton fraction (MPF) mapping combined with magnetic susceptibility measurements as subcortical biomarkers in Parkinson's disease (PD).

methodsTwenty patients with PD and 9 age-matched healthy controls underwent 3.0T magnetic resonance imaging, including MPF mapping and quantitative susceptibility mapping (QSM). MPF and magnetic susceptibility values of the 16 subcortical nuclei were measured in both the PD group and healthy control group, and these values were compared between the 2 groups. Diagnostic performance of MPF and magnetic susceptibility in the subcortical nuclei was individually evaluated using receiver operating characteristic (ROC) analysis. A logistic regression model was developed for the diagnosis of PD using a combination of MPF and magnetic susceptibility values.

resultsQuantitative analyses revealed significantly reduced MPF values (false discovery rate-corrected P < 0.05) in 7 subcortical nuclei in the PD group, namely the hypothalamus, parabrachial pigmented nucleus, red nucleus, substantia nigra pars reticulata, substantia nigra pars compacta, ventral pallidum, and ventral tegmental area. Additionally, magnetic susceptibility was significantly elevated (false discovery rate-corrected P < 0.05) in the parabrachial pigmented nucleus and substantia nigra pars compacta. ROC curve analysis demonstrated strong diagnostic performance, with the ventral pallidum showing the highest MPF-based diagnostic accuracy (area under the curve [AUC] = 0.82) and the substantia nigra pars compacta showing the highest QSM-based accuracy (AUC = 0.88). The logistic regression model combining MPF and magnetic susceptibility showed the best performance (AUC = 0.93).

conclusionMPF mapping, particularly when combined with magnetic susceptibility measurements, may serve as a quantitative diagnostic biomarker for PD, and the observed widespread alterations across multiple subcortical nuclei provide new insights into the pathology of PD beyond the classic nigrostriatal pathway.

Indexed as

BrainBrain MappingMagnetic Resonance ImagingParkinson DiseaseAgedBiomarkersCase-Control StudiesFemaleHumansMaleMiddle AgedProtonsROC CurveBiomarkersProtonsmacromolecular proton fraction mappingParkinson’s diseasesubcortical biomarkers

Identifiers

PMID41062303
PMCPMC13041249

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.